BioAtla (BCAB) Invested Capital (2020 - 2021)
BioAtla's (BCAB) quarterly Invested Capital came in at $210.8 million in Q4 2021, little changed on a YoY basis from $210.7 million in Q4 2020, and down 8.6% quarter-over-quarter from $230.7 million in Q3 2021.
Powered by 
Analysis
BioAtla (BCAB) Invested Capital (2020 - 2021) Analysis & Trends
BioAtla (BCAB) has reported Invested Capital for 2 consecutive years, with $210.8 million the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Invested Capital changed 0.08% year-over-year to $210.8 million; the trailing twelve-month figure through Dec 2021 stood at $210.8 million (changed 0.08% YoY), and the FY2021 full-year result was $210.8 million, changed 0.08% from the prior year.
- Invested Capital declined to $210.8 million in Q4 2021 per BCAB's latest filing, from $230.7 million in the prior quarter.
- Across five years, Invested Capital topped out at $230.7 million in Q3 2021 and bottomed at $178.7 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 74.44 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 40.49 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 33.70 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 7.35 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 26.94 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.30 Bn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 210.82 Mn |
| Sep 30, 2021 | 230.65 Mn |
| Jun 30, 2021 | 178.71 Mn |
| Mar 31, 2021 | 196.60 Mn |
| Dec 31, 2020 | 210.66 Mn |